SION - NASDAQ
Sionna Therapeutics, Inc.
$36.70
-10%Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
At a Glance
Live SnapshotSionna Therapeutics, Inc. Management Team
Ms. Elena H. Ridloff C.F.A.
Chief Financial Officer & Head of Corporate Development
Compensation
$647,922
Ms. Jennifer Fitzpatrick J.D.
Chief Legal Officer
Dr. Charlotte McKee M.D.
Chief Medical Officer
Compensation
$647,922
Ms. Vanya Sagar
Chief People Officer
Dr. Greg Hurlbut Ph.D.
Co-Founder & Senior Vice President of Discovery Research
Dr. Mark Munson Ph.D.
Co-founder & Senior Vice President of Medicinal Chemistry
Mr. Michael Cloonan M.B.A.
President, Chief Executive Officer & Director
Compensation
$784,593
Ms. Mara Furlow M.S.
Senior Vice President of Global Regulatory Affairs & Quality
Mr. Andy Chu
Vice President of Information & Technology
Ms. Meghan Bagshaw
Vice President of Programs, Portfolio & Operations
Sionna Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $104.66M worth of SION shares, with no buying activity reported.
3 Months
0
0.00
1.7M
77.57M
-77.6M
-$77.57M
3-6 Months
0
0.00
392.6K
16.25M
-16.2M
-$16.25M
6-9 Months
0
0.00
246.5K
10.84M
-10.8M
-$10.84M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Thompson Peter A.
Director
$46.55M
Orbimed Advisors Llc
Director
$46.55M
Tpg Gp A, Llc
10 Percent Owner
$10.00M
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$795K
Fitzpatrick Jennifer
Officer: Chief Legal Officer
$762K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $104.66M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
SION - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 12, 2025 | 2025 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.